Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support

Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Fabrizio Fabretti, Jonathan Morgan, Benjamin M.J. Owens, Karan Kanhai, Jim Cowburn, Marco Rizzi, Fabiano Di Marco, View ORCID ProfileAlessandro Rambaldi
doi: https://doi.org/10.1101/2020.04.01.20048561
Giuseppe Gritti
1Hematology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federico Raimondi
2Pneumology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diego Ripamonti
3Infectious Disease, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivano Riva
4Intensive Care, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Landi
1Hematology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leonardo Alborghetti
3Infectious Disease, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Frigeni
1Hematology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marianna Damiani
4Intensive Care, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caterina Micò
1Hematology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Fagiuoli
5Gastroenterology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roberto Cosentini
6Emergency Units, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ferdinando Luca Lorini
4Intensive Care, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrizio Fabretti
4Intensive Care, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Morgan
7EUSA Pharma, Breakspear Park, Hemel Hempstead, UK
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin M.J. Owens
7EUSA Pharma, Breakspear Park, Hemel Hempstead, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karan Kanhai
7EUSA Pharma, Breakspear Park, Hemel Hempstead, UK
MD PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jim Cowburn
7EUSA Pharma, Breakspear Park, Hemel Hempstead, UK
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco Rizzi
3Infectious Disease, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabiano Di Marco
2Pneumology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
8Departments of Health Sciences, University of Milan, Milan, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandro Rambaldi
1Hematology, Azienda Socio Sanitario Territoriale Papa Giovanni XXIII Hospital, Bergamo, Italy
9Departments of Oncology-Hematology, University of Milan, Milan, Italy
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandro Rambaldi
  • For correspondence: arambaldi@asst-pg23.it
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SAR-CoV-2), resulting in symptoms, such as fever, cough, and shortness of breath. The SARS-CoV-2 virus has also been suggested to initiate a cytokine storm in patients with COVID-19 evidenced by elevated cytokines, such as interleukin-6 (IL-6) and C-reactive protein (CRP).

We report preliminary data from 21 patients with COVID-19 who developed pneumonia/acute respiratory distress syndrome (ARDS) and participated in a compassionate-use program at Papa Giovanni XXIII hospital in Bergamo, Italy.

All 21 patients received intravenous siltuximab – a chimeric mAb that binds to and blocks the effect of IL-6 – at a dose ranging between 700 to 1,200 mg (median 900 mg). The median age of patients treated was 64 years, and all patients were followed for a median of eight days. Serum CRP levels reduced in all 16 patients with available data following treatment. An improvement in the clinical condition was observed in 33% (7/21) of patients, 43% (9/21) of patients stabilized as evidenced by no clinically relevant change in their condition, and 24% (5/21) experienced a worsening in their condition. Of those patients who experienced a worsening in their condition, one patient died, and one patient experienced a cerebrovascular event.

This analysis is presented to inform the medical community of the potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection, and a cohort study with patients treated with standard therapy in our hospital is ongoing, and will report the 30-day mortality rates upon completion.

Competing Interest Statement

Jonathan Morgan, Benjamin M.J. Owens, Karan Kanhai and Jim Cowburn are employees of EUSA Pharma. Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò;, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Fabrizio Fabretti, Marco Rizzi, Fabiano Di Marco and Alessandro Rambaldi have no competing interests.

Clinical Trial

NCT04322188

Funding Statement

EUSA Pharma funded data collection and processing, supported by Ergomed, and manuscript development, supported by TVF Communications.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data will be made available upon reasonable requests submitted to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 03, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Fabrizio Fabretti, Jonathan Morgan, Benjamin M.J. Owens, Karan Kanhai, Jim Cowburn, Marco Rizzi, Fabiano Di Marco, Alessandro Rambaldi
medRxiv 2020.04.01.20048561; doi: https://doi.org/10.1101/2020.04.01.20048561
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support
Giuseppe Gritti, Federico Raimondi, Diego Ripamonti, Ivano Riva, Francesco Landi, Leonardo Alborghetti, Marco Frigeni, Marianna Damiani, Caterina Micò, Stefano Fagiuoli, Roberto Cosentini, Ferdinando Luca Lorini, Fabrizio Fabretti, Jonathan Morgan, Benjamin M.J. Owens, Karan Kanhai, Jim Cowburn, Marco Rizzi, Fabiano Di Marco, Alessandro Rambaldi
medRxiv 2020.04.01.20048561; doi: https://doi.org/10.1101/2020.04.01.20048561

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (553)
  • Anesthesia (135)
  • Cardiovascular Medicine (1761)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (660)
  • Epidemiology (10803)
  • Forensic Medicine (8)
  • Gastroenterology (592)
  • Genetic and Genomic Medicine (2952)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1930)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (293)
  • HIV/AIDS (631)
  • Infectious Diseases (except HIV/AIDS) (12519)
  • Intensive Care and Critical Care Medicine (693)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2801)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1469)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (867)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2641)
  • Public and Global Health (5374)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (596)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)